Clinical trial · Interventional
E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.
E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer: Pilot Study
NCT04228432CI-TRIAL-00052914EPOPEEcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a monocentric, prospective cohort study evaluating the feasibility of an E-monitoring protocol in patients with breast cancer treated by adjuvant hormonotherapy . 45 patients will be included. Patients will be followed during 6 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dedicated and coordinated monitoring | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with breast cancer treated by adjuvant hormonotherapy
- interventionNames
- Other: Dedicated and coordinated monitoring
Primary outcomes (1)
- measure
- Rate of patients who do not fail the E-Monitoring protocol
- timeFrame
- 6 months per patient
Secondary outcomes (2)
- measure
- Number of medical consultations required over 6 months
- timeFrame
- 6 months per patient
- measure
- Rate of hormonotherapy adherence evaluated by the GIRERD questionnaire
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient treated for hormone-dependent localized breast cancer with adjuvant HT (tamoxifen or anti-aromatase +/- LHRH agonist) 2. Patient equipped with a computer or tablet computer and an internet connection at home 3. Age \> 18 years old 4. Patient affiliated to the french social security system 5. Patient who has signed informed consent before inclusion in the study and before any specific procedures for the study 6. Women of childbearing age should have effective contraception under hormonotherapy Exclusion Criteria: 1. Patient with breast cancer who does not require adjuvant hormonotherapy 2. Patient with metastatic breast cancer 3. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure 4. Patient previously treated for breast cancer (infiltrating or in-situ) with adjuvant HT or not 5. Patient protected by law.
References
Publications (0)
Data not yet available
No reference posted for this study.